Inference for Cumulative Incidences and Treatment Effects in Randomized Controlled Trials With Time-to-Event Outcomes Under ICH E9 (R1)
- PMID: 40386918
- DOI: 10.1002/sim.70091
Inference for Cumulative Incidences and Treatment Effects in Randomized Controlled Trials With Time-to-Event Outcomes Under ICH E9 (R1)
Abstract
In randomized controlled trials (RCTs) that focus on time-to-event outcomes, intercurrent events can arise in two ways: as semi-competing events, which modify the hazard of the primary outcome events, or as competing events, which make the definition of the primary outcome events unclear. Although five strategies have been proposed in the ICH E9 (R1) addendum to address intercurrent events in RCTs, these strategies are not easily applicable to time-to-event outcomes when aiming for causal interpretations. In this study, we show how to define, estimate, and make inferences concerning objectives that have causal interpretations within these contexts. Specifically, we derive the mathematical formulations of the causal estimands corresponding to the five strategies and clarify the data structure needed to identify these causal estimands. Furthermore, we introduce nonparametric methods for estimating and making inferences about these causal estimands, including the asymptotic variance of estimators and the construction of hypothesis tests. Finally, we illustrate our methods using data from the LEADER Trial, which aims to investigate the effect of liraglutide on cardiovascular outcomes.
Keywords: causal inference; estimand; intercurrent event; potential outcome; randomized controlled trial; survival analysis.
© 2025 John Wiley & Sons Ltd.
Similar articles
-
A Perspective on the Appropriate Implementation of ICH E9(R1) Addendum Strategies for Handling Intercurrent Events.Stat Med. 2025 May;44(10-12):e70104. doi: 10.1002/sim.70104. Stat Med. 2025. PMID: 40394856 Free PMC article.
-
Estimating hypothetical estimands with causal inference and missing data estimators in a diabetes trial case study.Biometrics. 2025 Jan 7;81(1):ujae167. doi: 10.1093/biomtc/ujae167. Biometrics. 2025. PMID: 39873640
-
Hypothetical Estimands in Clinical Trials: A Unification of Causal Inference and Missing Data Methods.Stat Biopharm Res. 2022 Jul 6;15(2):421-432. doi: 10.1080/19466315.2022.2081599. eCollection 2023. Stat Biopharm Res. 2022. PMID: 37260584 Free PMC article.
-
A narrative review of estimands in drug development and regulatory evaluation: old wine in new barrels?Trials. 2020 Jul 23;21(1):671. doi: 10.1186/s13063-020-04546-1. Trials. 2020. PMID: 32703247 Free PMC article. Review.
-
Is Intention to Treat Still the Gold Standard or Should Health Technology Assessment Agencies Embrace a Broader Estimands Framework?: Insights and Perspectives From the National Institute for Health and Care Excellence and Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use E9 (R1) Addendum.Value Health. 2023 Feb;26(2):234-242. doi: 10.1016/j.jval.2022.08.008. Epub 2022 Sep 21. Value Health. 2023. PMID: 36150999 Review.
Cited by
-
Realizing the benefits of the estimand framework when reporting and communicating clinical trial results-some recommendations.Trials. 2025 Jul 11;26(1):241. doi: 10.1186/s13063-025-08915-6. Trials. 2025. PMID: 40640873 Free PMC article.
References
-
- International Conference on Harmonization, “Addendum to Statistical Principles for Clinical Trials on Choosing Appropriate Estimands and Defining Sensitivity Analyses in Clinical Trials,” 2019. Step 4 version dated 20 November.
-
- K. Rufibach, “Treatment Effect Quantification for Time‐To‐Event Endpoints–Estimands, Analysis Strategies, and Beyond,” Pharmaceutical Statistics 18, no. 2 (2019): 145–165.
-
- B. C. Kahan, J. Hindley, M. Edwards, S. Cro, and T. P. Morris, “The Estimands Framework: A Primer on the ICH E9 (R1) Addendum,” BMJ 384 (2024): e076316.
-
- J. M. Siegel, H. J. Weber, S. Englert, F. Liu, M. Casey, and Pharmaceutical Industry Working Group on Estimands in Oncology, “Time‐To‐Event Estimands and Loss to Follow‐Up in Oncology in Light of the Estimands Guidance,” Pharmaceutical Statistics 23, no. 5 (2024): 709–727.
-
- A. Fierenz and A. Zapf, “Current Developments of the Estimand Concept,” Pharmaceutical Statistics 23 (2024): 864–869.
MeSH terms
Substances
Grants and funding
- 2021YFF0901400/National Key Research and Development Program of China
- 12026606/National Natural Science Foundation of China
- 12226005/National Natural Science Foundation of China
- 82304269/National Natural Science Foundation of China
- 2023-I2M-3-008/Chinese Academy of Medical Sciences Initiative for Innovative Medicine